Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among younger and older patients with psoriasis (< 65/≥ 65 years) in a post hoc analysis of 2 phase III trials (reSURFACE1/2, n = 1,862). Tildrakizu...

Full description

Bibliographic Details
Main Authors: Elke L. M. ter Haar, Juul M. P. A. van den Reek, Kristian Gaarn Du Jardin, Almudena Barbero-Castillo, Elke M. G. J. de Jong, Satish F. K. Lubeek
Format: Article
Language:English
Published: Medical Journals Sweden 2023-10-01
Series:Acta Dermato-Venereologica
Subjects:
adverse drug events
clinical efficacy
clinical trials, Phase III as topic
older adults, frail
tildrakizumab
Online Access:https://medicaljournalssweden.se/actadv/article/view/17752

Internet

https://medicaljournalssweden.se/actadv/article/view/17752

Similar Items